Search the Newsreel

How Investors May Respond To Arcus Biosciences (RCUS) Expanding ARC-20 With New Kidney Cancer Combo

Arcus Biosciences is expanding its ARC-20 platform with a new kidney cancer combination involving its HIF-2a inhibitor casdatifan and Summit Therapeutics' PD-1/VEGF bispecific antibody ivonescimab. This collaboration allows both companies to retain rights to their drugs while sharing costs, potentially broadening their kidney cancer …

Marcus (NYSE:MCS) Stock Rating Upgraded by Wall Street Zen

Marcus (MCS) Stock Pullback Follows Record Quarter And Valuation Questions

Marcus & Millichap Arranges Sale of Park Hill Apartments in Kerrville Texas

Marcus & Millichap has announced the sale of Park Hill, a 49-unit apartment property in Kerrville, Texas. The property, built in 1977, was marketed by Ben Kalter, Will Balthrope, and Drew Garza and was acquired by a Boerne-based buyer who plans to implement renovations …

Marcus & Millichap Arranges Sale of Multifamily Mixed-Use Property in Chicago

Marcus & Millichap announced the sale of a mixed-use property at 5655 West Fullerton Avenue in Chicago, featuring 24 multifamily units and four retail suites. The property, built in 1970, was sold to a private investor who sees significant value-add opportunities, including leasing vacant …

Marcus & Millichap Inc (MMI) Institutional Confidence

Marcus & Millichap Inc (MMI) has a high institutional shareholding score of 10.00, ranking 1st in the Real Estate Operations industry. The institutional shareholding proportion is 110.81%, showing a 15.07% increase quarter-over-quarter. Richard Pzena is the largest institutional shareholder, holding 1.89M shares, representing 5.32% …

Marcus Q2 Earnings Call Highlights

MARCUS CORP : B. RILEY CUTS TO NEUTRAL FROM BUY; RAISES TARGET PRICE TO $29 FROM $27

B. Riley has downgraded Marcus Corp (MCS.N) to "Neutral" from "Buy" but increased the target price to $29 from $27. This change in rating and target price reflects an updated outlook from the analyst firm for the company.

Marcus Corp. sees big stock price boost after strong earnings report

B. Riley Financial Downgrades Marcus (NYSE:MCS) to Neutral

MCS | The Marcus Corporation Financials - Income Statement

Marcus Corp. profit more than doubles as blockbuster movies drive record quarter

Marcus Corp. saw its net earnings more than double, jumping 116% in the second quarter of fiscal 2026, driven by the strong performance of blockbuster films. Both its theater and hotel divisions outperformed their respective industries, contributing to a combined revenue of $231.74 million. …

Earnings call transcript: The Marcus Corporation tops Q2 2026 estimates

The Marcus Corporation (MCS) reported stronger-than-expected Q2 2026 results, exceeding analyst estimates with earnings of $0.51 per share and revenue of $231.7 million. The company's performance was driven by a robust film slate leading to higher theater attendance and increased demand in its hotels …

Marcus & Millichap Sells 18-Unit Property in Boston for $4.875M

Marcus & Millichap has sold the Delhi Street Portfolio, an 18-unit, three-building multifamily property in Boston's Mattapan neighborhood, for $4.875 million. The property, built in 1930, offers value-add potential and is located near public transit, attracting investors looking for stable cash flow and long-term …

Marcus & Millichap Arranges Sale of 134-Unit Value-Add Multifamily Portfolio in Berwyn and Maywood Illinois

Marcus & Millichap has announced the sale of a 134-unit multifamily portfolio in Berwyn and Maywood, Illinois. The portfolio was acquired by a local private investor and consists of five apartment buildings, offering the buyer immediate scale and value-add opportunities. The sale represents a …

Marcus: Q2 Earnings Snapshot

This article provides a Q2 earnings snapshot for Marcus. However, the full content of the article was not provided, only the title and publication information.

Marcus Corp: Same Store Admission Rev for 2Q Increased 16.6% Compared to the Prior Yr Qtr >MCS

This article provides a financial update for Marcus Corp (MCS), highlighting a significant 16.6% increase in same-store admission revenue for the second quarter compared to the previous year. This key metric indicates strong performance in their core operations.

MARCUS CORP Q2 2026: Revenue $231.7M, EPS $0.51— 10-Q Summary

MARCUS CORP (MCS) reported strong second-quarter 2026 results with revenue of $231.7 million and diluted EPS of $0.51, significantly up from the prior year. This growth was fueled by improved theatre and hotel operations, including increased admissions, concessions, and RevPAR. The company also implemented …

Marcus Corp (NYSE: MCS) Q2 2026 profit more than doubles on revenue growth

Marcus Corporation reported a significant increase in Q2 2026 profit, which more than doubled due to a 12.5% rise in total revenues to $231.7 million. Operating income also saw a substantial gain to $27.1 million from $13.0 million, with diluted EPS growing to $0.51 …

Marcus Corp (MCS) Q2 2026 Earnings

Marcus Corp (MCS) reported a strong Q2 2026, surpassing EPS estimates by 47.1% with earnings of $0.51 against an estimated $0.35. Revenue also exceeded expectations, reaching $232 million compared to an estimated $220 million, a 5.4% beat. The positive results were driven by record …

Marcus Corporation (NYSE: MCS) Q2 2026 revenue hits $231.7M

Marcus Corporation reported strong Q2 2026 financial results, with total revenues increasing by 12.5% to $231.7 million and net earnings more than doubling to $15.8 million, or $0.51 per diluted share. Both its Theatre and Hotels & Resorts divisions significantly outperformed their respective industries, …

Marcus & Millichap (MMI) Expected to Announce Quarterly Earnings on Thursday

Marcus & Millichap (NYSE:MMI) is expected to release its Q2 2026 earnings before market open on Thursday, August 6th, with analysts forecasting earnings of $0.03 per share on revenue of $194.30 million. The company previously reported an EPS of ($0.08) in Q1 2026 and …

Marcus Corporation Reports Second Quarter Fiscal 2026 Results

The Marcus Corporation reported strong second-quarter fiscal 2026 results, with total revenues up 12.5% to $231.7 million and net earnings increasing by 116.4% to $15.8 million compared to the prior year. Both its Marcus Theatres and Marcus Hotels & Resorts divisions outperformed their respective …

Compared to Estimates, Marcus (MCS) Q2 Earnings: A Look at Key Metrics

Marcus (NYSE:MCS) Issues Quarterly Earnings Results, Beats Estimates By $0.17 EPS

Marcus (NYSE:MCS) Stock Price Up 18.9% Following Earnings Beat

Marcus (MCS) Tops Q2 Earnings and Revenue Estimates

Marcus & Millichap Arranges Sale of Lincoln Family Housing in Ruston Louisiana

Marcus & Millichap announced the sale of Lincoln Family Housing, a 40-unit apartment property in Ruston, Louisiana. The transaction involved a Denver-based seller and a Ruston-based buyer, facilitated by Evan De Blanc, Nick Fluellen, Bard Hoover, and John T. McGregor from Marcus & Millichap's …

Law firm probes Arcus Biosciences officers for possible self-dealing harming shareholders

A law firm, Kuehn Law, PLLC, is investigating officers and directors of Arcus Biosciences, Inc. for potential self-dealing and breaches of fiduciary duties. This investigation could result in shareholder damages and lead to corporate governance reforms. Long-term shareholders are advised to seek a free …

Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Arcus Biosciences, Inc. (NYSE: RCUS) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled …

RCUS|Arcus Biosciences Inc|Price:26.470|Chg%:-0.580

This article provides a comprehensive stock analysis of Arcus Biosciences Inc (RCUS) by TradingKey, highlighting its stable fundamentals, significant growth potential, and a "fairly valued" rating within the Biotechnology & Medical Research industry. The company, a clinical-stage biopharmaceutical firm focused on cancer therapies, shows …

MMI|Marcus & Millichap Inc|Price:30.845|Chg%:-0.765

Marcus & Millichap Inc (MMI) shows relatively healthy fundamentals and high growth potential, with its valuation considered fairly valued within the Real Estate Operations industry. Institutional ownership is notably high, and despite average recent stock performance, the company's stock is trading sideways between support …

Marcus & Millichap Negotiates $6 Million Sale of Retail Property in Pottstown, Pennsylvania

Marcus & Millichap has successfully negotiated the $6 million sale of the Upland Square retail pads in Pottstown, Pennsylvania. The property, consisting of two buildings totaling 10,944 square feet, was fully occupied at the time of sale by tenants such as Aspen Dental, Starbucks …

Arcus Biosciences Inc (RCUS) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Arcus Biosciences Inc (RCUS), highlighting its volatility, financial risks, and investment risks. The company's current risk assessment score is 4.64, ranking it 67 out of 385 in the Biotechnology & Medical Research industry, with a beta of …

Marcus Corporation Promotes Rajiv W. Castellino to Chief Information Officer

Marcus Corporation has announced the promotion of Rajiv W. Castellino to Chief Information Officer, effective August 2, 2026. Castellino, who previously served as chief technology officer of Marcus Hotels & Resorts, will succeed Kim M. Lueck upon her retirement. He brings over 30 years …

Arcus Biosciences (RCUS) Projected to Post Quarterly Earnings on Wednesday